53
Participants
Start Date
August 30, 2022
Primary Completion Date
July 31, 2026
Study Completion Date
December 31, 2027
Nirogacestat
nirogacestat oral tablet
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Institute, New York
Greater Baltimore Medical Center, Baltimore
AdventHealth Orlando, Orlando
Orlando Health Cancer Institute, Orlando
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Women's Cancer Center at Kettering, Kettering
Froedtert and Medical College of Wisconsin, Milwaukee
David C. Pratt Cancer Center, St Louis
Women's Cancer Care, Covington
OU Health Stephenson Cancer Center, Oklahoma City
University of New Mexico Comprehensive Cancer Center, Albuquerque
USC/Norris Comprehensive Cancer Center, Los Angeles
UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit, Los Angeles
UW/Fred Hutch Cancer Center, Seattle
Dana-Farber Cancer Institute, Boston
Cross Cancer Institute, Edmonton
Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok
Jagiellonian Innovation Centre Clinical Research Centre, Krakow
University Teaching Hospital Poznan, Department of Oncological Gynaecology, Poznan
Maria Sklodowska-Curie National Institute of Oncology-National Research Institute, Clinic of Oncological Gynecology, Warsaw
SpringWorks Therapeutics, Inc.
INDUSTRY